Inflammatory cytokines and nuclear factor-kappa B activation in adolescents with bipolar and major depressive disorders.

TitleInflammatory cytokines and nuclear factor-kappa B activation in adolescents with bipolar and major depressive disorders.
Publication TypeJournal Article
Year of Publication2016
AuthorsMiklowitz DJ, Portnoff LC, Armstrong CC, Keenan-Miller D, Breen EC, Muscatell KA, Eisenberger NI, Irwin MR
JournalPsychiatry Res
Volume241
Pagination315-22
Date Published2016 Jul 30
ISSN1872-7123
Abstract

UNLABELLED: Adults with bipolar disorder (BD) and major depressive disorder (MDD) have higher circulating levels of proinflammatory cytokines than healthy controls. However, it is not known whether pediatric-onset patients with BD or MDD show increases in levels of inflammation or activation of nuclear factor kappa B (NF-κB), a key transcription factor in inflammatory signaling. Circulating levels of inflammatory cytokines, as well as spontaneous and stimulated levels of activated NF-κB in total peripheral blood mononuclear cells, monocytes and lymphocytes were measured in adolescents with BD (n=18), MDD (n=13), or no psychiatric history (n=20). Participants had a range of mood symptoms at time of testing. Adolescents with BD had significantly higher spontaneous levels of NF-κB in peripheral blood mononuclear cells, monocyte and lymphocyte populations, and higher plasma levels of IL-1β than healthy controls. Following stimulation with recombinant human TNF-α, participants with BD and MDD both had greater increases in NF-κB in monocytes than controls. Further, greater stimulated increases of NF-κB in monocytes were associated with the current severity of depressive symptoms. The results are limited by the small sample and cross-sectional design. Interventions that target early immunological dysregulation should be examined in relation to long-term outcomes in youth with bipolar and depressive disorders.

CLINICAL TRIAL REGISTRATION INFORMATION: Early Intervention for Youth at Risk for Bipolar Disorder, https://clinicaltrials.gov/ct2/show/NCT01483391.

DOI10.1016/j.psychres.2016.04.120
Alternate JournalPsychiatry Res
PubMed ID27227701
PubMed Central IDPMC4912920
Grant ListR01 MH093676 / MH / NIMH NIH HHS / United States
R21 MH097007 / MH / NIMH NIH HHS / United States
R33 MH097007 / MH / NIMH NIH HHS / United States